Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

Novo Nordisk’s SOUL trial confirms that oral semaglutide significantly reduces the risk of heart attack, stroke, and ...

The researchers saw a 26% reduction in non-fatal heart attacks with oral semaglutide and a 12% reduction in non ... “The same cardiovascular benefits can be derived from the tablet that we’ve seen ...

💊 A new international clinical trial found that oral semaglutide ... population prone to heart attacks, strokes, and related complications, showing similar benefits to its injectable counterpart.

McGuire, MD, MHSc, professor of medicine in the division of cardiology, Dallas Heart Ball Chair ... support the fact that oral semaglutide will generate the same CV benefits as the rest of the ...

Trial confirms that oral semaglutide lowers cardiovascular risk in type 2 diabetes, regardless of SGLT2i use. Read more!

“The same cardiovascular benefits can be derived from ... The 26% reduction in the rate of non-fatal heart attack among patients taking oral semaglutide was the primary driver of the improvement ...

A new international clinical trial has shown that the oral form of semaglutide, a medication already known for managing type ...

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide ... benefits they’re looking for. Some patients with a personal or family history of heart ...

Recent study shows oral semaglutide reduces cardiovascular risk in type 2 diabetes patients, enhancing diabetes and heart ...